A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and ...
Real-world evidence shows switching between etanercept products and etanercept biosimilars preserves efficacy and safety, ...
Scoping review shows clinicians and patients still worry about biosimilar insulin switching, devices and safety—evidence gaps ...
One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable safety and immunogenicity outcomes.
Biologics eat 51% of drug spending despite 5% of prescriptions, but FDA's new draft guidance hopes more competition can close that gap.
Celltrion leads biosimilars in Asia, biosimilars in Europe expand, while Sandoz restructures and FDA hurdles loom.
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results